Patents by Inventor David Lodge

David Lodge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polemonium plant named 'Polelodge'
    Publication number: 20170295709
    Abstract: A new and distinct cultivar of Polemonium plant named ‘Polelodge’, characterized by its basal clumping habit; dense and bushy appearance; numerous green and yellow variegated leaves; small violet blue-colored flowers; long flowering period; and good garden performance.
    Type: Application
    Filed: April 11, 2016
    Publication date: October 12, 2017
    Inventor: David Lodge
  • Interactive advertising display
    Publication number: 20090303033
    Abstract: An interactive advertising display that has a display element, a transmitter operative to output a wireless signal in response to movement, and a receiver for receiving the signal from the transmitter. The receiver is connected to the display element so as to turn the display on and off in response to the signal from the transmitter.
    Type: Application
    Filed: June 6, 2008
    Publication date: December 10, 2009
    Inventors: David Wiesenfeld, David Lodge
  • Method of treating stroke
    Publication number: 20040063680
    Abstract: The present invention provides a method of treating stroke in a patient comprising administering to said patient an effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 5, 2003
    Publication date: April 1, 2004
    Inventors: James Allen Clemens, David Lodge
  • Assay for evaluating the affinity of compounds to the glutamate GluR5 receptor
    Patent number: 6245521
    Abstract: A hippocampal GluR5 receptor modulator, 2-amino-3-(3 2-amino-3-(3-hydroxy-5-tert-butylisoxazol-4-yl)propanoic acid (ATPA) is useful in methods of measuring the binding affinity of chemical compounds to GluR5 receptors.
    Type: Grant
    Filed: March 3, 1999
    Date of Patent: June 12, 2001
    Assignee: Eli Lilly and Company
    Inventors: David Bleakman, David Lodge
  • Pharmacological agents
    Patent number: 6242462
    Abstract: Antagonists selective for the GluR5 receptor are useful for the treatment of pain. Also disclosed are novel decahydroisoquinoline derivatives which are selective GluR5 receptor antagonists.
    Type: Grant
    Filed: February 22, 2000
    Date of Patent: June 5, 2001
    Assignee: Eli Lilly and Company
    Inventors: David Bleakman, David R. Helton, Iyengar Smriti, David Lodge, Paul L Ornstein
  • Electrical component
    Patent number: 5406031
    Abstract: An electrical component has a body (1) and a plurality of leads extending from the body, and is enclosed in an insulating plastics sleeve (4) that extends over the body and leads. The sleeve (4) has a number of heat-recoverable end portions (6, 7) that extend over the leads and enclose a quantity of solder (8, 9), so that the leads can be permanently connected to further terminals by heating the end portions of the sleeves to cause them to recover and the solder to fuse.
    Type: Grant
    Filed: May 6, 1994
    Date of Patent: April 11, 1995
    Assignee: Raychem S.A.
    Inventors: Gerard Mathieu, Frederic F. Passa, David Lodge
  • plant named ‘Polelodge’
    Patent number: PP28653
    Abstract: A new and distinct cultivar of Polemonium plant named ‘Polelodge’, characterized by its basal clumping habit; dense and bushy appearance; numerous green and yellow variegated leaves; small violet blue-colored flowers; long flowering period; and good garden performance.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: November 14, 2017
    Inventor: David Lodge